US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

Maravai LifeSciences Holdings Inc

us-stock
To Invest in {{usstockname}}
us-stock
$3.51 0.0203(2.03%) MRVI at 04 Dec 2025 04:39 PM Biotechnology
Lowest Today 3.43
Highest Today 3.52
Today’s Open 3.445
Prev. Close 3.44
52 Week High 6.21
52 Week Low 1.67
Day’s Range: Low 3.43 High 3.52
52-Week Range: Low 1.67 High 6.21
1 day return -
1 Week return -2.77
1 month return +22.29
3 month return +48.1
6 month return +58.1
1 year return -35.18
3 year return -73.71
5 year return -87.31
10 year return -

Institutional Holdings

GTCR LLC 13.93

12 West Capital Management LP 8.65

BlackRock Inc 6.70

Vanguard Group Inc 6.48

BRAIDWELL LP 5.77

Mackenzie Investments 4.20

Canada Life US Small-Mid Cap Growth F 3.16

Renaissance Technologies Corp 2.89

Vanguard Total Stock Mkt Idx Inv 2.72

Mirabella Financial Services LLP 2.59

Point72 (DIFC) Ltd 2.57

UBS Group AG 2.23

iShares Russell 2000 ETF 2.08

Geode Capital Management, LLC 2.06

Morgan Stanley - Brokerage Accounts 1.99

T. Rowe Price Investment Management,Inc. 1.83

Philosophy Capital Management LLC 1.79

State Street Corp 1.65

Two Sigma Advisers, LLC 1.54

T. Rowe Price Small-Cap Stock 1.35

Tejara Capital Ltd 1.34

Deutsche Bank AG 1.30

Systematic Financial Management LP 1.16

CenterBook Partners LP 1.13

Vanguard Small Cap Index 0.97

Vanguard Institutional Extnd Mkt Idx Tr 0.90

Fidelity Small Cap Index 0.85

Columbia Small Cap Value Discv A 0.79

Columbia Small Cap Value Discovery Fund 0.77

T. Rowe Price Small-Cap Value 0.76

Xtrackers MSCI World Swap ETF 1C 0.75

iShares Russell 2000 Value ETF 0.73

T. Rowe Price Instl Small-Cap Stock 0.68

Vanguard Small Cap Growth Index Inv 0.54

Xtrackers S&P 500 Swap ETF 1C 0.51

Royce Micro Cap Trust 0.49

Fidelity Extended Market Index 0.46

iShares Biotechnology ETF 0.44

Pender Global Small/Mid Cap Eq F 0.42

IG Mackenzie U.S. Small-Mid Cap Growth C 0.42

Market Status

Strong Buy: 5

Buy: 1

Hold: 7

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 1260.38 M

PB Ratio 2.1389

PE Ratio 0.0

Enterprise Value 649.35 M

Total Assets 1008.24 M

Volume 655385

Company Financials

Annual Revenue FY23:419517000 419.5M, FY22:883001000 883.0M, FY21:799240000 799.2M, FY20:284098000 284.1M, FY19:143140000 143.1M

Annual Profit FY23:252629000 252.6M, FY22:714044000 714.0M, FY21:658679000 658.7M, FY20:204449000 204.4M, FY19:76291000 76.3M

Annual Net worth FY23:24564000 24.6M, FY22:490663000 490.7M, FY21:469250000 469.3M, FY20:88972000 89.0M, FY19:-5201000 -5.2M

Quarterly Revenue Q3/2025:41630000 41.6M, Q2/2025:47397000 47.4M, Q1/2025:46850000 46.9M, Q3/2024:65200000 65.2M, Q2/2024:73400000 73.4M

Quarterly Profit Q3/2025:5655000 5.7M, Q2/2025:7768000 7.8M, Q1/2025:7725000 7.7M, Q3/2024:28374000 28.4M, Q2/2024:35129000 35.1M

Quarterly Net worth Q3/2025:-25556000 -25.6M, Q2/2025:-39591000 -39.6M, Q1/2025:-29945000 -29.9M, Q3/2024:-99038000 -99.0M, Q2/2024:-7585000 -7.6M

Fund house & investment objective

Company Information Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 550

Industry Biotechnology

CEO Mr. Bernd Brust

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right